Aspirin as an Adjunctive Pharmacologic Therapy Option for COVID-19: Anti-Inflammatory, Antithrombotic, and Antiviral Effects All in One Agent.
Udaya S TantryKarsten SchrorEliano Pio NavareseYoung-Hoon JeongJacek KubicaKevin P BlidenPaul A GurbelPublished in: Journal of experimental pharmacology (2021)
Aspirin targets the intracellular signaling pathway that is essential for viral replication, and resultant inflammatory responses, hypercoagulability, and platelet activation. With these multiple benefits, aspirin can be a credible adjunctive therapeutic option for the treatment of COVID-19. In addition, inhaled formulation with its rapid effects may enhance direct delivery to the lung, which is the key organ damaged in COVID-19 during the critical initial course of the disease, whereas the 150-325 mg/day can be used for long-term treatment to prevent thrombotic event occurrences. Being economical and widely available, aspirin can be exploited globally, particularly in underserved communities and remote areas of the world to combat the ongoing COVID-19 pandemic.
Keyphrases
- sars cov
- coronavirus disease
- low dose
- cardiovascular events
- antiplatelet therapy
- signaling pathway
- anti inflammatory
- coronary artery disease
- respiratory syndrome coronavirus
- type diabetes
- atrial fibrillation
- pi k akt
- cardiovascular disease
- combination therapy
- drug delivery
- stem cells
- bone marrow
- cystic fibrosis
- mesenchymal stem cells
- cell proliferation
- replacement therapy
- reactive oxygen species
- induced apoptosis
- oxidative stress